Literature DB >> 31095692

Urinary Excretion Profile of 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol (THCCOOH) Following Smoked and Vaporized Cannabis Administration in Infrequent Cannabis Users.

Tory R Spindle1, Edward J Cone1, Nicolas J Schlienz1, John M Mitchell2, George E Bigelow1, Ronald Flegel3, Eugene Hayes3, Ryan Vandrey1.   

Abstract

As cannabis has become more accessible, use of alternative methods for cannabis administration such as vaporizers has become more prevalent. Most prior controlled pharmacokinetic evaluations have examined smoked cannabis in frequent (often daily) cannabis users. This study characterized the urinary excretion profile of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH), the primary analytical outcome for detection of cannabis use, among infrequent cannabis users following controlled administration of both smoked and vaporized cannabis. Healthy adults (N = 17), with a mean of 398 (range 30-1,825) days since last cannabis use, smoked and vaporized cannabis containing 0, 10, and 25 mg of Δ9-tetrahydrocannabinol (THC) across six outpatient sessions. Urinary concentrations of THCCOOH were measured at baseline and for 8 h after cannabis administration. Sensitivity, specificity, and agreement between three immunoassays (IA) for THCCOOH (with cutoffs of 20, 50, and 100 ng/mL) and gas chromatography-mass spectrometry (GC/MS) results (confirmatory concentration of 15 ng/mL) were assessed. THCCOOH concentrations peaked 4-6 h after cannabis administration. Median maximum concentrations (Cmax) for THCCOOH were qualitatively higher after administration of vaporized cannabis compared to equal doses of smoked cannabis. Urine THCCOOH concentrations were substantially lower in this study relative to prior examinations of experienced cannabis users. The highest agreement between IA and GC/MS was observed at the 50 ng/mL IA cutoff while sensitivity and specificity were highest at the 20 and 100 ng/mL IA cutoffs, respectively. Using federal workplace drug-testing criteria (IA cutoff of 50 ng/mL and GC/MS concentration ≥15 ng/mL) urine specimens tested positive in 47% of vaporized sessions and 21% of smoked sessions with active THC doses (N = 68). Urinary concentrations of THCCOOH are dissimilar after administration of smoked and vaporized cannabis, with qualitatively higher concentrations observed after vaporization. Infrequent users of cannabis may excrete relatively low concentrations of THCCOOH following acute inhalation of smoked or vaporized cannabis.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31095692      PMCID: PMC8205504          DOI: 10.1093/jat/bkz038

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  24 in total

1.  Differentiating new marijuana use from residual drug excretion in occasional marijuana users.

Authors:  M A Huestis; E J Cone
Journal:  J Anal Toxicol       Date:  1998-10       Impact factor: 3.367

2.  Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake.

Authors:  Matthew N Newmeyer; Madeleine J Swortwood; Allan J Barnes; Osama A Abulseoud; Karl B Scheidweiler; Marilyn A Huestis
Journal:  Clin Chem       Date:  2016-10-10       Impact factor: 8.327

3.  Excretion patterns of cannabinoid metabolites after last use in a group of chronic users.

Authors:  G M Ellis; M A Mann; B A Judson; N T Schramm; A Tashchian
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

4.  Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana.

Authors:  M A Huestis; J M Mitchell; E J Cone
Journal:  J Anal Toxicol       Date:  1996-10       Impact factor: 3.367

5.  Plasma and urine profiles of Delta9-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes.

Authors:  Rudolf Brenneisen; Pascale Meyer; Haithem Chtioui; Martial Saugy; Matthias Kamber
Journal:  Anal Bioanal Chem       Date:  2010-01-30       Impact factor: 4.142

6.  Online survey characterizing vaporizer use among cannabis users.

Authors:  Dustin C Lee; Benjamin S Crosier; Jacob T Borodovsky; James D Sargent; Alan J Budney
Journal:  Drug Alcohol Depend       Date:  2015-12-30       Impact factor: 4.492

7.  Cannabis smoke condensate III: the cannabinoid content of vaporised Cannabis sativa.

Authors:  B Pomahacova; F Van der Kooy; R Verpoorte
Journal:  Inhal Toxicol       Date:  2009-11       Impact factor: 2.724

8.  High School Students' Use of Electronic Cigarettes to Vaporize Cannabis.

Authors:  Meghan E Morean; Grace Kong; Deepa R Camenga; Dana A Cavallo; Suchitra Krishnan-Sarin
Journal:  Pediatrics       Date:  2015-09-07       Impact factor: 7.124

9.  "Hallucinations" Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs.

Authors:  Frederick S Barrett; Nicolas J Schlienz; Natalie Lembeck; Muhammad Waqas; Ryan Vandrey
Journal:  Cannabis Cannabinoid Res       Date:  2018-03-01

10.  Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis: A Crossover Trial.

Authors:  Tory R Spindle; Edward J Cone; Nicolas J Schlienz; John M Mitchell; George E Bigelow; Ronald Flegel; Eugene Hayes; Ryan Vandrey
Journal:  JAMA Netw Open       Date:  2018-11-02
View more
  2 in total

1.  Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis.

Authors:  Francesco Paolo Busardò; Ana Pilar Pérez-Acevedo; Roberta Pacifici; Giulio Mannocchi; Massimo Gottardi; Esther Papaseit; Clara Pérez-Mañá; Soraya Martin; Lourdes Poyatos; Simona Pichini; Magí Farré
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-13

2.  E-cigarette Product Use, or Vaping, Among Persons with Associated Lung Injury - Illinois and Wisconsin, April-September 2019.

Authors:  Isaac Ghinai; Ian W Pray; Livia Navon; Kevin O'Laughlin; Lori Saathoff-Huber; Brooke Hoots; Anne Kimball; Mark W Tenforde; Jennifer R Chevinsky; Mark Layer; Ngozi Ezike; Jonathan Meiman; Jennifer E Layden
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-10-04       Impact factor: 17.586

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.